Pds biotech strengthens intellectual property portfolio governing a combination of versamune® and pds0301

Florham park, n.j., july 11, 2023 (globe newswire) -- pds biotechnology corporation (nasdaq: pdsb), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced the canadian intellectual property office has allowed patent number 2,876,656 titled, “cationic lipid vaccine combinations and methods of use,” governing composition of matter and uses for versamune® (r-dotap) in combination with pds0301. the intellectual property provides broad protection for treatments utilizing versamune® based therapies, including pds0101, in combination with pds0301 as a potential treatment for cancer. this patent expands pds biotech's market coverage and adds to the world-wide patent portfolio including the patent granted by the united states patent and trademark office (uspto), u.s. patent no. 11,401,306, covering the combination of versamune® and cytokines including interleukin 12 (il-12).
PDSB Ratings Summary
PDSB Quant Ranking